Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College.
Peking University Fifth School of Clinical Medicine, Beijing.
Int J Surg. 2024 Apr 1;110(4):2104-2114. doi: 10.1097/JS9.0000000000001140.
Sacral neuromodulation (SNM) has emerged as an effective therapy for refractory lower urinary tract dysfunction (LUTD). Remote programming holds promise in addressing the time and economic burdens associated with outpatient programming, especially for patients in the observation period following Stage I implant surgery (where the lead is implanted first without the pulse generator). The study aimed to explore the effectiveness and patient satisfaction of remote programming for Stage I SNM patients, and analyze the benefits patients gain from remote programming.
This prospective study was conducted at multiple high-level clinical SNM centres in China. Patients requiring SNM implantation were enroled and divided into two groups based on patient preference: remote programming (RP) group and outpatient control (OC) group. Patient attitudes toward RP were assessed through questionnaires, and the degree of symptom improvement was compared between the two groups to explore the usability of RP.
A total of 63 participants from 6 centres were included in the study, with 32 belonging to the RP group. The remote programming system presents a high level of usability (98%) and willingness (satisfaction rate: 96.83%) in result of questionnaire. RP showed a significant advantage in improving patients' score of ICSI/ICPI (medianΔICSI/ICPI RP vs. OC= -13.50 vs -2, P =0.015). And slightly ameliorate urinary symptoms such as pain (medianΔVAS RP vs. OC= -1 vs 0, P = 0.164) and urgency (medianΔOBASS -2.5 vs. -1, P = 0.,229), but the difference was not statistically significant. RP did not significantly impact the quality of life of patients ( P =0.113), so do the rate of phase-two conversion ( P = 0.926) or programming parameters.
To the best of our knowledge, the presented study is the first multicenter research focusing on the remote programming of Stage I SNM patients. Through the clinical implementation and patient feedback, we demonstrate that remote programming is not inferior to in-person programming in terms of success rate, effectiveness, safety, and patient satisfaction.
骶神经调节(SNM)已成为治疗难治性下尿路功能障碍(LUTD)的有效方法。远程程控有望解决与门诊程控相关的时间和经济负担,尤其是对于 I 期植入手术后的观察期患者(此时仅植入电极而不植入脉冲发生器)。本研究旨在探讨远程程控在 I 期 SNM 患者中的有效性和患者满意度,并分析患者从远程程控中获得的收益。
本前瞻性研究在中国多家高水平临床 SNM 中心进行。招募需要 SNM 植入的患者,并根据患者的偏好将其分为远程程控(RP)组和门诊对照组(OC)组。通过问卷调查评估患者对 RP 的态度,并比较两组患者的症状改善程度,以探讨 RP 的可用性。
共有来自 6 个中心的 63 名参与者纳入本研究,其中 32 名患者属于 RP 组。远程程控系统的可用性(98%)和意愿(满意度:96.83%)均很高。RP 在改善患者 ICSI/ICPI 评分方面具有显著优势(RP 组与 OC 组的中位数ΔICSI/ICPI= -13.50 比 -2,P=0.015)。同时,RP 略微改善了疼痛(RP 组与 OC 组的中位数ΔVAS= -1 比 0,P=0.164)和尿急(RP 组与 OC 组的中位数ΔOBASS= -2.5 比 -1,P=0.229)等尿症状,但差异无统计学意义。RP 并未显著影响患者的生活质量(P=0.113),也未影响二期转换率(P=0.926)或程控参数。
据我们所知,本研究是首次关注 I 期 SNM 患者远程程控的多中心研究。通过临床实施和患者反馈,我们证明远程程控在成功率、有效性、安全性和患者满意度方面并不逊于面对面程控。